Monday December 21, 2015 0 comments
CENTENNIAL -- AlloSource, one the largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, announced it has been awarded a patent for its flagship regenerative medicine product, AlloStem Cellular Bone Allograft.
U.S. Patent No. 9,192,695 highlights AlloStem’s partially de-mineralized allograft bone combined with adipose-derived mesenchymal stem cells.
Suitable for general bone grafting applications, AlloSource said AlloStem is similar to autograft bone because it provides the three key properties needed for bone formation: scaffold, signal and cells.
“Receiving this patent is a big milestone not just for our research and development team, but also for our whole company,” said Thomas Cycyota, AlloSource president and CEO.
“Our motivation to develop innovative products is driven by our mission to maximize the gift of donation and advance healing for tissue recipients.”
The AlloStem patent is one of several in its growing portfolio of living cell and tissue patents, the company said.